Showing 361 - 380 results of 18,204 for search '(( significantly reported decrease ) OR ( significantly ((a decrease) OR (linear decrease)) ))', query time: 0.72s Refine Results
  1. 361
  2. 362
  3. 363
  4. 364
  5. 365

    Participant retention flowchart. by Carolin Oetzmann (11397968)

    Published 2025
    “…We used latent class and latent transition analysis to identify subtypes at baseline, determined their consistency at 6- and 12-month follow-ups, and examined transitions over time. We identified a 4-class solution: (1) severe with appetite decrease, (2) severe with appetite increase, (3) moderate severity and (4) low severity. …”
  6. 366
  7. 367
  8. 368
  9. 369

    Raw data. by Saeedeh Abbasi (9423189)

    Published 2025
    “…However, both groups exhibited a significant decrease in CCI during prolonged standing (time *  condition: p =  0.003). …”
  10. 370

    Data. by Saeedeh Abbasi (9423189)

    Published 2025
    “…However, both groups exhibited a significant decrease in CCI during prolonged standing (time *  condition: p =  0.003). …”
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376
  17. 377

    Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

    Published 2024
    “…Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). …”
  18. 378

    S1 Data - by Kazuyoshi Ohkawa (836847)

    Published 2024
    “…Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). …”
  19. 379

    S1 Graphical abstract - by Aman Goyal (19231397)

    Published 2025
    “…</p><p>Results</p><p>Between 1999 and 2020, 155,320 deaths were reported in patients with paroxysmal tachycardia. Overall, AAMR decreased from 4.8 to 3.7 per 100,000 population between 1999 and 2020, despite showing a significant increase from 2014 to 2020 (APC: 4.33; 95% CI: 3.53 to 5.56). …”
  20. 380

    DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…<p>Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystemic disease with a multifactorial pathogenesis involving dietary, environmental, and genetic factors. …”